论文部分内容阅读
针对HIV-1包膜蛋白的中和抗体在体外高度有效地抑制不同病毒株的侵染, 但在体内只以很低水平存在, 提出多中和表位-表位疫苗作为提高体内中和抗体水平及机体抗病毒变异能力的新战略. 两种候选多中和表位-表位疫苗在猴体内能同时诱导出预先确定的多中和表位特异性的抗体. 这些抗体能识别表位多肽、gp41多肽、V3 loop 多肽、rsgp41和gp120上相应的中和表位. 此外, 3个实验型表位疫苗的组合(另一种形式的多中和表位-表位疫苗)在兔体内也诱导出类似的免疫应答. 上述实验结果表明：多中和表位-表位疫苗可能是一种能同时诱导多重抗病毒活性、抗HIV-1感染以及对付病毒变异的新战略.
Neutralizing antibodies directed against the HIV-1 envelope protein are highly effective in inhibiting infection by different virus strains in vitro but only in very low levels in vivo, suggesting that the multi-neutralizing epitope-epitope vaccine is an antibody that enhances neutralizing antibodies in vivo Level and the ability of the body to antivirally mutate.The two candidate multi-neutralizing epitope-epitope vaccines can simultaneously induce pre-determined multi-neutralizing epitope-specific antibodies in monkeys that recognize epitope peptides , The gp41 polypeptide, the V3 loop polypeptide, the corresponding neutralizing epitopes on rsgp41 and gp120 In addition, the combination of three experimental epitope vaccines (another form of the multi-neutralizing epitope-epitope vaccine) Induced a similar immune response.The above experimental results show that: The multi-neutralizing epitope-epitope vaccine may be a new strategy that can simultaneously induce multiple antiviral activity, anti-HIV-1 infection and the fight against virus mutation.